GSK's Cancer Drug Mo-Rez Shrinks Tumours in Majority of Patients in Early Trial

GSK Unveils Promising Results for Targeted Cancer Therapy

GSK has presented positive early-stage trial data for its experimental cancer drug mocertatug rezetecan, known as Mo-Rez, showing the therapy shrank tumours in a majority of patients with hard-to-treat gynaecological cancers. The results were presented at the Society of Gynecologic Oncology's twenty twenty six Annual Meeting on Women's Cancer in San Juan, Puerto Rico.

Strong Response Rates in Difficult-to-Treat Cancers

In the phase one BEHOLD-1 trial, Mo-Rez achieved confirmed objective response rates of sixty two percent in thirty four patients with platinum-resistant ovarian cancer at the highest dose, and sixty seven percent in twelve patients with recurrent or advanced endometrial cancer. More than half of the patients enrolled had already received two or more prior lines of therapy, a population with five-year survival rates of just twenty to thirty percent. Median follow-up reached six months for the ovarian cancer group and four months for endometrial cancer patients.

Safety Profile Clears Path Forward

The safety data offered encouragement. Interstitial lung disease, a toxicity associated with some approved antibody-drug conjugates, occurred in only around four percent of patients across both groups. Treatment-related adverse events led to discontinuation in just two percent of ovarian cancer patients and four percent of endometrial cancer patients.

Five Phase Three Trials Planned

GSK plans to launch five global phase three trials in the coming months, beginning with studies in platinum-resistant ovarian cancer and second-line endometrial cancer. Additional trials will evaluate Mo-Rez in platinum-sensitive ovarian cancer, front-line ovarian cancer, and first-line endometrial cancer. Mo-Rez is a B7-H4-targeted antibody-drug conjugate that GSK licensed from China's Hansoh Pharma in October twenty twenty three. GSK's oncology head Hesham Abdullah expressed confidence in the drug's blockbuster potential, calling the response rates extremely exciting.